Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment failure on front-line imatinib than on nilotinib. Patients with suboptimal res...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hughes, Timothy P., Hochhaus, Andreas, Kantarjian, Hagop M., Cervantes, Francisco, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D., Rosti, Gianantonio, Ossenkoppele, Gert, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D., Kemp, Charisse, Larson, Richard A., Saglio, Giuseppe
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2014
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077082/
https://ncbi.nlm.nih.gov/pubmed/24532039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.091272
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars